相关实验视频

Updated: Jan 14, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

同时的炎症性肠病会损害生物反应,并增加牛皮关节炎的残留症状负担

Maria Morrone¹, Vincenzo Venerito¹, Maria Grazia Giannotta¹

¹Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Italy.

Seminars in arthritis and rheumatism

|October 17, 2025

概括

患有牛皮关节炎和炎症性肠病 (IBD) 的患者对生物疗法的反应减少. 这凸显了对于这个复杂的患者群体需要个性化治疗策略的必要性.

科学领域:

类风湿病学类风湿病学
胃肠病学胃肠病学
免疫学免疫学免疫学

背景情况:

牛皮关节炎 (PsA) 和炎症性肠病 (IBD) 是慢性炎症性疾病.
针对TNF抑制剂或IL-12/23通路的生物疗法用于PSA.
同时IBD对PsA治疗反应的影响尚未完全理解.

研究的目的:

为了研究并发性IBD对PsA患者生物治疗反应的影响.
确定在6个月内实现最小疾病活性 (MDA) 和DAPSA缓解/低疾病活性 (LDA) 的预测因素.

主要方法:

开始使用生物药物的PsA患者 (PsA-IBD与只有PsA) 的回顾性,匹配的队列研究 (2011-2023年).
匹配标准包括年龄,性别,疾病持续时间和生物类.
临床评估和患者报告的结果 (PROs) 在基线,6个月和12个月使用多变量逻辑回归分析.

主要成果:

与只有PsA患者相比,PSA-IBD患者 (n=60) 的MDA (32.1%) 和DAPSA缓解/LDA (50.0%) 在6个月后的比率显著降低 (分别为58.3%和78.3%;p<0.01).
同时的IBD是实现MDA (aOR 0.28) 的可能性较低的独立预测因素,并显示了与减少DAPSA反应 (aOR 0.39) 的边界关联.
在12个月后,PsA-IBD患者报告疼痛和全球疾病活性得分更高.

结论:

同时的IBD与PsA生物治疗的临床反应受损有关.
患有PSA-IBD的患者经历了更大的残留症状负担.
针对性治疗策略是必要的PsA患者与同时存在的IBD.

关键词:

生物学上的DMARDs.炎症性肠病是一种炎症性肠病.患者报告的结果牛皮关节炎牛皮关节炎治疗结果的结果.

更多相关视频

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

Chronic Bowel Disorders: Introduction

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...